Changes in Immunogenicity during the Development of Urinary Bladder Cancer: A Preliminary Study

Area of Science:

• Oncology
• Immunology
• Urothelial Carcinoma Research

Background:

• Bladder cancer progression involves complex immune interactions.
• Tumor-infiltrating lymphocytes (TILs) and regulatory T lymphocytes (Tregs) play critical roles in antitumor responses.
• Understanding immune cell dynamics is crucial for effective bladder cancer treatment.

Purpose of the Study:

• To evaluate the expression of TILs and blood Tregs in bladder cancer patients.
• To correlate immune cell counts with clinico-pathomorphological features and clinical outcomes.
• To explore the implications of these findings for immunotherapy selection.

Main Methods:

• Analysis of CD4+, CD8+, CD20+ TILs and CD4+/CD25+/FoxP3+ Tregs in bladder cancer tissues and blood.
• Association of immune cell numbers with tumor stage, differentiation, invasion, and patient prognosis.
• Comparison of immune cell profiles between different tumor stages and post-surgical treatment.

Main Results:

• Decreased TILs observed in advanced, metastasizing tumors with non-classic differentiation and aggressive invasion.
• Low CD4+ TIL count was linked to poor prognosis.
• Reduced Treg frequency noted in advanced tumors, both pre- and post-surgery.
• Changes in TILs and Tregs correlated with histological phenotype (pT stage, NDs, TIT) and outcomes.

Conclusions:

• TILs and blood Tregs serve as indicators of antitumor response and may guide immunotherapy selection based on tumor growth phase.
• Reduced CD4+ and CD8+ TILs in advanced tumors with non-classic differentiation suggest lower immunogenicity and immune tolerance.
• Complex interactions between bladder cancer immunogenicity and progression stages, including heterogeneous differentiation, warrant further investigation.